MIDD can be applied to all therapeutic areas. This blog highlights its application to oncology drug development. This approach can inform all stages of cancer drug development from early to late clinical development. It allows us to understand an investigational oncology drug’s PK, safety, and efficacy, first in nonclinical species. Then this information can be translated to first-in-human studies where it can inform the dosing strategy (dose, dosing intervals, dose schedule, and dose…
